Titlebook: Bisphosphonates and Tumor Osteolysis; Kurt W. Brunner,Herbert Fleisch,Hans-J?rg Senn Conference proceedings 1989 Springer-Verlag Berlin He

敏捷

Treatment of Tumor-Induced Osteolysis by APD,be lethal. It is primarily caused by malignant diseases (Fisken et al. 1980). Hypercalcemia of malignancy, also called “hypercalcemia of cancer,” “malignant hypercalcemia,” or “tumor-induced hypercalcemia,” is one of the most common metabolic complications of cancer (Mundy et al. 1984), and its cumu

Ptosis

Clodronate Therapy of Metastatic Bone Disease in Patients with Prostatic Carcinoma,mission of some length, the final outcome is frequently progressive skeletal disease, despite orchiectomy and/or continuous hormone therapy. At this stage, the efficacy of cytotoxic drugs is limited (Posner et al. 1977) and radiation therapy is used only in persons with epidural spinal cord compress

侵略

Effect of Long-Term Bisphosphonate Treatment on Morbidity Due To Bone Metastases in Breast Cancer Pf these patients suffer from osteolytic bone metastases at some time during the course of their disease (Elte et al. 1986). Hypercalcemia is a frequent complication in patients with extensive lesions in the skeleton. Osteolytic bone metastases cause severe morbidity and often incapacitate the patien

遠地點

9樓

arabesque

10樓

圓錐體

10樓

噱頭

10樓

捐助

10樓